Allman-Farinelli MA, Aitken RJ, King LA, Bauman AE. Osteoarthritis-the forgotten obesity-related epidemic with worse to come. The Medical journal of Australia. 2008; 188:317. PMID: 18312205
Katz JD, Agrawal S, Velasquez M. Getting to the heart of the matter: osteoarthritis takes its place as part of the metabolic syndrome. Curr Opin Rheumatol. 2010; 22:512-9. doi: 10.1097/BOR.0b013e32833bfb4b PMID: 20592604
Conde J, Gomez R, Bianco G, Scotece M, Lear P, Dieguez C, et al. Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis. 2011; 70:551-9. doi: 10.1136/ard.2010.132399 PMID: 21216818
Sowers MR, Karvonen-Gutierrez CA. The evolving role of obesity in knee osteoarthritis. Curr Opin Rheumatol. 2010; 22:533-7. doi: 10.1097/BOR.0b013e32833b4682 PMID: 20485173
Dahaghin S, Bierma-Zeinstra SM, Koes BW, Hazes JM, Pols HA. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. Ann Rheum Dis. 2007; 66:916-20. PMID: 17314121
Davies-Tuck ML, Hanna F, Davis SR, Bell RJ, Davison SL, Wluka AE, et al. Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middleaged women-a prospective cohort study. Arthritis Res Ther. 2009; 11:R181. doi: 10.1186/ar2873PMID: 19961577
Erb N, Pace AV, Douglas KM, Banks MJ, Kitas GD. Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 2004; 33:293-9. PMID: 15513676
Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. The American journal of managed care. 2002; 8:S383-91. PMID: 12416788
Tsezou A, Iliopoulos D, Malizos KN, Simopoulou T. Impaired expression of genes regulating cholesterol efflux in human osteoarthritic chondrocytes. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2010; 28:1033-9. doi: 10.1002/jor.21084 PMID: 20108316
Gkretsi V, Simopoulou T, Tsezou A. Lipid metabolism and osteoarthritis: lessons from atherosclerosis. Progress in lipid research. 2011; 50:133-40. doi: 10.1016/j.plipres.2010.11.001 PMID: 21115041
de Seny D, Cobraiville G, Charlier E, Neuville S, Esser N, Malaise D, et al. Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties. PloS one. 2013; 8:e66769.doi: 10.1371/journal.pone.0066769 PMID: 23776697
Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993; 102:131-46. PMID: 7504491
Annema W, Nijstad N, Tolle M, de Boer JF, Buijs RV, Heeringa P, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). Journal of lipid research. 2010; 51:743-54. doi: 10. 1194/jlr.M000323 PMID: 20061576
Chiba T, Chang MY, Wang S, Wight TN, McMillen TS, Oram JF, et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arteriosclerosis, thrombosis, and vascular biology. 2011; 31:1326-32. doi: 10.1161/ATVBAHA. 111.226159 PMID: 21474830
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986; 29:1039-49. PMID: 3741515
Arnett FC, Edworthy SM, Bloch DA, MacShane DJ, Fries JF, Cooper N. The American Rheumatism Association1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315-24. PMID: 3358796
Relic B, Benoit V, Franchimont N, Kaiser MJ, Hauzeur JP, Gillet P, et al. Peroxisome proliferatoractivated receptor-gamma1 is dephosphorylated and degraded during BAY 11-7085-induced synovial fibroblast apoptosis. J Biol Chem. 2006; 281:22597-604. PMID: 16766531
Relic B, Bentires-Alj M, Ribbens C, Franchimont N, Guerne PA, Benoit V, et al. TNF-alpha protects human primary articular chondrocytes from nitric oxide-induced apoptosis via nuclear factor-kappaB. Lab Invest. 2002; 82:1661-72. PMID: 12480916
Relic B, Zeddou M, Desoroux A, Beguin Y, de Seny D, Malaise MG. Genistein induces adipogenesis but inhibits leptin induction in human synovial fibroblasts. Lab Invest. 2009; 89:811-22. doi: 10.1038/ labinvest.2009.41 PMID: 19434061
Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Molecular pharmacology. 2011; 79:34-41. doi: 10.1124/mol.110.068064 PMID: 20881006
Oliviero F, Lo Nigro A, Bernardi D, Giunco S, Baldo G, Scanu A, et al. A comparative study of serum and synovial fluid lipoprotein levels in patients with various arthritides. Clin Chim Acta. 2012; 413:303-7. doi: 10.1016/j.cca.2011.10.019 PMID: 22037510
Busso N, Dudler J, Salvi R, Peclat V, Lenain V, Marcovina S, et al. Plasma apolipoprotein(a) codeposits with fibrin in inflammatory arthritic joints. Am J Pathol. 2001; 159:1445-53. PMID: 11583972
Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A, et al. Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol. 2009; 27:79-83. PMID: 19327233
Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem. 2013; 288:21237-52.doi: 10.1074/jbc.M113.468967 PMID: 23720750
Onat A, Can G, Ornek E, Cicek G, Murat SN, Yuksel H. Increased apolipoprotein A-I levels mediate the development of prehypertension among Turks. Anadolu kardiyoloji dergisi: AKD = the Anatolian journal of cardiology. 2013; 13:306-14. doi: 10.5152/akd.2013.106 PMID: 23591583
Onat A, Hergenc G, Bulur S, Ugur M, Kucukdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. International journal of cardiology. 2010; 142:72-9. doi: 10.1016/j.ijcard.2008.12.066 PMID: 19171400
Chiang SL, Ou TT, Wu YJ, Tu HP, Lu CY, Huang CM, et al. Increased level of MSU crystal-bound protein apolipoprotein A-I in acute gouty arthritis. Scand J Rheumatol. 2014:1-5. doi: 10.3109/03009742. 2013.805242 PMID: 25521915
Solomon A, Murphy CL, Kestler D, Coriu D, Weiss DT, Makovitzky J, et al. Amyloid contained in the knee joint meniscus is formed fromapolipoprotein A-I. Arthritis Rheum. 2006; 54:3545-50. PMID: 17075859
BeckWH, Adams CP, Biglang-Awa IM, Patel AB, Vincent H, Haas-Stapleton EJ, et al. Apolipoprotein A-I binding to anionic vesicles and lipopolysaccharides: role for lysine residues in antimicrobial properties. Biochim Biophys Acta. 2013; 1828:1503-10. doi: 10.1016/j.bbamem.2013.02.009 PMID: 23454085
van der Heijden IM, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM, Hazenberg MP, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum. 2000; 43:593-8. PMID: 10728753
Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, et al. Overexpression of toll-like receptors3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008; 58:3684-92. doi: 10.1002/art.24140 PMID: 19035519
Onat A, Can G, Ornek E, Sansoy V, Aydin M, Yuksel H. Abdominal obesity with hypertriglyceridaemia, lipoprotein(a) and apolipoprotein A-I determine marked cardiometabolic risk. Eur J Clin Invest. 2013; 43:1129-39. doi: 10.1111/eci.12150 PMID: 24020867
Onat A, Can G, Ayhan E, Kaya Z, Hergenc G. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. Metabolism: clinical and experimental. 2009; 58:1393-9.doi: 10.1016/j.metabol.2009.05.004 PMID: 19570555
Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. Journal of lipid research. 1996; 37:2473-91. PMID: 9017501
Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological reviews. 2006; 58:342-74. PMID: 16968945
Luscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circulation research. 2014; 114:171-82. doi: 10.1161/CIRCRESAHA.114.300935 PMID: 24385510
Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, et al. Translation of highdensity lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013; 128:1256-67. doi: 10.1161/CIRCULATIONAHA.113.000962 PMID: 24019446
Santos-Gallego CG, Rosenson RS. Role of HDL in those with diabetes. Current cardiology reports. 2014; 16:512. doi: 10.1007/s11886-014-0512-5 PMID: 25199216
Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta. 2008; 397:42-7. doi: 10.1016/j.cca.2008.07.014 PMID: 18691566
de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis. 2012; 222:390-4. doi: 10. 1016/j.atherosclerosis.2012.02.032 PMID: 22456230
Farbstein D, Levy AP. HDL dysfunction in diabetes: causes and possible treatments. Expert review of cardiovascular therapy. 2012; 10:353-61. doi: 10.1586/erc.11.182 PMID: 22390807
